menu
    • menu
    [{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abiraterone decanoate","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Abiraterone decanoate","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Propella Therapeutics \/ Propella Therapeutics"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Propella Therapeutics \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Propella Therapeutics \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Propella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Abiraterone Decanoate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Propella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Abiraterone Decanoate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Abiraterone Decanoate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Astellas Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Propella Therapeutics

    Menu

    Propella Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abiraterone Decanoate,Dexamethasone,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $175.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Astellas completes acquisition of Propella Therapeutics

                            Details : Through the acquisition, Astellas has acquired PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.

                            Brand Name : PRL-02

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 21, 2023

                            Lead Product(s) : Abiraterone Decanoate,Dexamethasone,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $175.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abiraterone Decanoate,Prednisone,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $175.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Astellas to Acquire Propella Therapeutics

                            Details : Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.

                            Brand Name : PRL-02

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 15, 2023

                            Lead Product(s) : Abiraterone Decanoate,Prednisone,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $175.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abiraterone Decanoate,Prednisone,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advance...

                            Details : PRL-02 (abiraterone decanoate) is routed through the lymph to target tissues where it releases the precise level of abiraterone needed to block CYP17 lyase for 12 weeks, thereby reducing interim tumor breakthrough risk.

                            Brand Name : PRL-02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 14, 2023

                            Lead Product(s) : Abiraterone Decanoate,Prednisone,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abiraterone Decanoate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostat...

                            Details : PRL-02 (abiraterone decanoate), is long-acting, selective CYP17 lyase inhibitor that has been designed for optimal uptake through lymphatic system so that a precise level of abiraterone can be released to continuously block CYP17 lyase over a three-month...

                            Brand Name : PRL-02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2022

                            Lead Product(s) : Abiraterone Decanoate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm)...

                            Details : Under the terms of the agreement, ASK Pharm will have exclusive rights to develop, manufacture and commercialize CGS-200-5 for the Greater China region. Topical CGS-200-5 has clinically been shown to significantly reduce OA knee pain.

                            Brand Name : CGS-200-5

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 07, 2022

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abiraterone Decanoate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate...

                            Details : Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.

                            Brand Name : PRL-02

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 23, 2021

                            Lead Product(s) : Abiraterone Decanoate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Propella Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abiraterone Decanoate

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer

                            Details : The patent covers new molecules that are designed to provide significant advantages over the current standard of care. The patent, titled Abiraterone Prodrugs, protects certain novel prodrugs.

                            Brand Name : PRL-02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 07, 2020

                            Lead Product(s) : Abiraterone Decanoate

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth